Incyte (INCY) and MorphoSys (MOR) Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab in Combination with Lenalidomide

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Incyte (INCY) and MorphoSys (MOR) Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab in Combination with Lenalidomide

Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo

December 14, 2021 4:31 PM EST

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura) a topical JAK inhibitor, as a potential treatment for adolescents and adults (age 12 years) with vitiligo. The FDA grants Priority Review to medicines that may offer a major advance in treatment where none currently exists. The Prescription Drug User... More

Why EV Lucid (LCID) Shares Soared in Pre Open Trading Today

December 13, 2021 5:09 AM EST

Shares of Lucid Group (NASDAQ: LCID) are up nearly 7% in pre-open today after Nasdaq announced it will add the LCID stock to its Nasdaq-100 Index as of December 2021.

Lucid shares will be included together with Airbnb, Inc. (Nasdaq:... More